Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H17FN4O3 |
Molecular Weight | 368.3617 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C1=CC=C(F)C([C@@H]2C[C@@H]2NC(=O)NC3=CC=C(C=N3)C#N)=C1O
InChI
InChIKey=NKPHEWJJTGPRSL-OCCSQVGLSA-N
InChI=1S/C19H17FN4O3/c1-2-15(25)11-4-5-13(20)17(18(11)26)12-7-14(12)23-19(27)24-16-6-3-10(8-21)9-22-16/h3-6,9,12,14,26H,2,7H2,1H3,(H2,22,23,24,27)/t12-,14+/m1/s1
MIV-150 is a tight-binding, allosteric inhibitor of reverse transcriptase that is active against HIV-1 and HIV-2. MIV-150 has been shown to inactivate viruses that are resistant to other antiviral drugs, including non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors. MIV-150 effectively inactivated free virus. Combination of MIV-150 and Carraguard demonstrated an additive antiviral effect. Seminal fluid had no effect on the antiviral activity of MIV-150 or Carraguard. The average concentration that blocks 50% of infection (EC50) for PC-815 was approximately 10 times stronger than Carraguard for the different clinical isolates used in the study.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27437826
4 g of PC-1005 (MIV-150/zinc acetate in a carrageenan gel)
Route of Administration:
Vaginal
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
824VSI942Y
Created by
admin on Sat Dec 16 09:32:36 GMT 2023 , Edited by admin on Sat Dec 16 09:32:36 GMT 2023
|
PRIMARY | |||
|
DTXSID70177773
Created by
admin on Sat Dec 16 09:32:35 GMT 2023 , Edited by admin on Sat Dec 16 09:32:35 GMT 2023
|
PRIMARY | |||
|
9907284
Created by
admin on Sat Dec 16 09:32:36 GMT 2023 , Edited by admin on Sat Dec 16 09:32:36 GMT 2023
|
PRIMARY | |||
|
231957-54-3
Created by
admin on Sat Dec 16 09:32:35 GMT 2023 , Edited by admin on Sat Dec 16 09:32:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY